Literature DB >> 33322363

Haloperidol Induced Cell Cycle Arrest and Apoptosis in Glioblastoma Cells.

Fotios Papadopoulos1, Rafaela Isihou1, George A Alexiou1, Thomas Tsalios2, Evrysthenis Vartholomatos1, Georgios S Markopoulos3, Chrissa Sioka1, Pericles Tsekeris4, Athanasios P Kyritsis1, Vasiliki Galani2.   

Abstract

Although several antipsychotic drugs have been shown to possess anticancer activities, haloperidol, a "first-generation" antipsychotic drug, has not been extensively evaluated for potential antineoplastic properties. The aim of this study was to investigate the antitumoral effects of haloperidol in glioblastoma (GBM) U87, U251 and T98 cell lines, and the effects of combined treatment with temozolomide (TMZ) and/or radiotherapy, using 4 Gy of irradiation. The viability and proliferation of the cells were evaluated with trypan blue exclusion assay and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis, using the annexin-propidium iodide (PI), and cell cycle, cluster of differentiation (CD) expression and caspase-8 activation were measured using flow cytometry. Treatment with haloperidol significantly reduced cell viability in U87, U251 and T98 GBM cell lines. Haloperidol induced apoptosis in a dose-dependent manner, inhibited cell migration and produced an alteration in the expression of CD24/CD44. The additional effect of haloperidol, combined with temozolomide and radiation therapy, increased tumor cell death. Haloperidol was observed to induce apoptosis and to increase caspase-8 activation. In conclusion, haloperidol may represent an innovative strategy for the treatment of GBM and further studies are warranted in glioma xenograft models and other malignancies.

Entities:  

Keywords:  antipsychotic; apoptosis; glioblastoma cells; haloperidol

Year:  2020        PMID: 33322363      PMCID: PMC7763579          DOI: 10.3390/biomedicines8120595

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  43 in total

Review 1.  G-protein-coupled receptors and cancer.

Authors:  Robert T Dorsam; J Silvio Gutkind
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

2.  Predicting blood-brain transport of drugs: a computational approach.

Authors:  S C Basak; B D Gute; L R Drewes
Journal:  Pharm Res       Date:  1996-05       Impact factor: 4.200

3.  Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival.

Authors:  Yanhong Liu; Sanjay Shete; Carol J Etzel; Michael Scheurer; George Alexiou; Georgina Armstrong; Spyros Tsavachidis; Fu-Wen Liang; Mark Gilbert; Ken Aldape; Terri Armstrong; Richard Houlston; Fay Hosking; Lindsay Robertson; Yuanyuan Xiao; John Wiencke; Margaret Wrensch; Ulrika Andersson; Beatrice S Melin; Melissa Bondy
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

4.  Moschamine inhibits proliferation of glioblastoma cells via cell cycle arrest and apoptosis.

Authors:  George A Alexiou; Diamanto Lazari; Georgios Markopoulos; Evrysthenis Vartholomatos; Entela Hodaj; Vasiliki Galani; Athanasios P Kyritsis
Journal:  Tumour Biol       Date:  2017-05

5.  Influence of glioma's multidrug resistance phenotype on (99m)Tc-tetrofosmin uptake.

Authors:  George A Alexiou; Anna Goussia; Athanasios P Kyritsis; Spyridon Tsiouris; Antigoni Ntoulia; Vassiliki Malamou-Mitsi; Spyridon Voulgaris; Andreas D Fotopoulos
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

Review 6.  Long-term survival in a patient with glioblastoma on antipsychotic therapy for schizophrenia: a case report and literature review.

Authors:  Shahdabul Faraz; Susan Pannullo; Marc Rosenblum; Andrew Smith; A Gabriella Wernicke
Journal:  Ther Adv Med Oncol       Date:  2016-08-18       Impact factor: 8.168

Review 7.  Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis.

Authors:  J Vermeulen; G van Rooijen; P Doedens; E Numminen; M van Tricht; L de Haan
Journal:  Psychol Med       Date:  2017-04-11       Impact factor: 7.723

8.  Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation.

Authors:  Mohamed Rafiuddin Ahmed; Vsevolod V Gurevich; Kevin N Dalby; Jeffrey L Benovic; Eugenia V Gurevich
Journal:  J Pharmacol Exp Ther       Date:  2008-01-04       Impact factor: 4.030

9.  A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.

Authors:  Isabel Arrillaga-Romany; Andrew S Chi; Joshua E Allen; Wolfgang Oster; Patrick Y Wen; Tracy T Batchelor
Journal:  Oncotarget       Date:  2017-05-12

10.  Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases.

Authors:  Wei Zhang; Cunlong Zhang; Feng Liu; Yu Mao; Wei Xu; Tingting Fan; Qinsheng Sun; Shengnan He; Yuzong Chen; Wei Guo; Ying Tan; Yuyang Jiang
Journal:  Sci Rep       Date:  2018-10-25       Impact factor: 4.379

View more
  4 in total

1.  Antiproliferative activity of CD44 siRNA-PEI-PEG nanoparticles in glioblastoma: involvement of AKT signaling.

Authors:  Parvaneh Mahinfar; Ahad Mokhtarzadeh; Behzad Baradaran; Elham Siasi Torbati
Journal:  Res Pharm Sci       Date:  2021-11-11

Review 2.  Drug Repurposing: The Mechanisms and Signaling Pathways of Anti-Cancer Effects of Anesthetics.

Authors:  King-Chuen Wu; Kai-Sheng Liao; Li-Ren Yeh; Yang-Kao Wang
Journal:  Biomedicines       Date:  2022-07-04

Review 3.  Repurposing Antipsychotics for Cancer Treatment.

Authors:  Nikolaos Vlachos; Marios Lampros; Spyridon Voulgaris; George A Alexiou
Journal:  Biomedicines       Date:  2021-11-28

Review 4.  Mechanisms of Cell Cycle Arrest and Apoptosis in Glioblastoma.

Authors:  Konstantinos Gousias; Theocharis Theocharous; Matthias Simon
Journal:  Biomedicines       Date:  2022-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.